Uriviga S Tablet contains Tamsulosin 400mcg + Solifenacin 6mg, a dual-action therapy for effective management of urinary disorders, including bladder outlet obstruction and overactive bladder. Tamsulosin relaxes the urinary tract muscles for improved flow, while Solifenacin reduces bladder overactivity, ensuring comprehensive symptom control and patient comfort.
This tablet is highly trusted by prescribers due to its consistent efficacy and tolerability, creating steady demand. Patients benefit from improved urinary function, reduced frequency, and relief from urinary urgency, enhancing treatment adherence.
For franchise partners, Uriviga S Tablet represents a high-demand urology therapy product with strong market acceptance. Its proven clinical performance and prescriber confidence make it a profitable addition to urology portfolios, supporting business growth and customer loyalty.
With its combination of urinary relief and bladder health support, Uriviga S Tablet offers sustainable sales potential, making it an ideal choice for partners serving the urology and urinary care market.
Common side effects may include dry mouth, constipation, dizziness, blurred vision, headache, and mild gastrointestinal discomfort. Some patients may experience fatigue, palpitations, or urinary retention. Any severe or persistent symptoms should be reported to a healthcare professional immediately.
Uriviga S Tablet is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, nocturia, and urge incontinence. It is also useful in patients with bladder outlet obstruction due to benign prostatic hyperplasia, where combination therapy is needed to improve both storage and voiding symptoms.
Uriviga S Tablet should be taken exactly as prescribed by a healthcare professional. Patients with severe kidney or liver impairment, glaucoma, or urinary retention should use this medication cautiously. Do not exceed the recommended dose, and report any unusual urinary or cardiovascular symptoms promptly.
Store Uriviga S Tablet in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children and do not use after the expiry date mentioned on the pack.